Semaglutide and medication-overuse headache

Medication-overuse headache (MOH) affects an estimated 1 to 2 percent of the general population and sits at the intersection of chronic pain and addictive behaviour. People with frequent migraine attacks often increase their use of analgesics or triptans, and that escalation can produce a self-reinforcing cycle in which the medication itself drives daily or near-daily headache. An editorial published on 7 August 2026 in Expert Opinion on Pharmacotherapy by Lanfranco Pellesi and Simona Guerzoni asks a specific question: could GLP-1 receptor agonists address this addiction-like component?^[1]

What medication-overuse headache actually is

MOH is classified by the International Headache Society as headache occurring on 15 or more days per month in a person who was already experiencing a primary headache disorder and who has been overusing acute medication for at least three months. The threshold varies by drug class: triptans can produce MOH at 10 or more days per month; simple analgesics and opioids require at least 15 days per month. ^[1] What makes MOH difficult to treat is not the diagnosis itself but the underlying behaviour. Research using addiction assessment tools has found that patients with chronic migraine and MOH score significantly higher on craving, motivation to use, and addiction severity than patients with chronic migraine alone who have not overused medication.^[2]

Brain imaging shows parallel changes. Studies report alterations in serotonin and dopamine functional connectivity within reward-processing regions including the nucleus accumbens and the caudate that are present in MOH patients and shift with effective treatment.^[3] The reward-circuit involvement is what connects MOH, at least conceptually, to the pharmacology of GLP-1 receptor agonists.

Why GLP-1 agonists enter this conversation

Semaglutide and other GLP-1 receptor agonists are licensed for type-2 diabetes and weight management. Their relevance to the MOH question comes from a separate body of research showing that GLP-1 receptors are present in brain regions that regulate reward and craving, including the ventral tegmental area and the striatum. In animal models, GLP-1 receptor activation reduces cue-induced seeking of alcohol, nicotine, and other reinforcing substances. That overlap with the reward pathway is what Pellesi and Guerzoni point to in their editorial.^[1]

The editorial keywords signal the specific mechanisms under discussion: CGRP (calcitonin gene-related peptide, the neuropeptide central to migraine pathophysiology), addiction, pain, and semaglutide. The argument threading these terms is that a drug capable of dampening reward-seeking behaviour might also reduce the compulsive analgesic use that defines MOH, while separately acting on the CGRP axis that underlies migraine attacks. That is a two-mechanism hypothesis, not a single pharmacological action.

What observational data exist

The most direct population-level data come from a Danish interrupted time series published two days before the editorial. Roland and colleagues used nationwide health registers to track 189,392 adults who initiated semaglutide between December 2022 and December 2024. Triptan use had been rising in this group before initiation. After initiation, the trend reversed: at 12 months there was a 7 percent relative reduction in triptan consumption (decline of 13 defined daily doses per month per 10,000 individuals, 95% CI: -25 to -1.3).^[4] The reduction was stronger in females (8 percent) and in adults aged 18 to 35 (14 percent). Among people with prior antimigraine prophylaxis use, the reduction reached 12 percent.

That is a meaningful signal in a large national dataset. The caveat the authors are careful to note is that the study cannot separate mechanisms: people starting semaglutide are losing weight, and weight reduction is itself associated with migraine frequency reduction. The triptan signal could reflect better migraine control from weight loss rather than a direct CNS effect on analgesic-seeking behaviour. Disentangling these pathways requires a different study design.

Safety context: headache as an adverse event

Before accepting the hypothesis without caveat, there is a tension worth noting. GLP-1 receptor agonists are themselves associated with headache as an adverse event. A pharmacovigilance analysis of the FDA Adverse Event Reporting System found a headache reporting odds ratio of 1.74 and a migraine reporting odds ratio of 1.28 for the GLP-1 drug class.^[5] Spontaneous reporting databases overrepresent adverse events and cannot establish causation, but the signal is part of the picture. A larger propensity-score matched cohort study using electronic health records from over 100 million US patients found that semaglutide was not associated with an increased risk of neurological or psychiatric outcomes including migraine over 12 months of follow-up.^[6] The two data sources point in different directions, which is itself informative: the safety picture is not settled.

What the research gap looks like

The Pellesi and Guerzoni editorial is an opinion piece, not a trial report. Its value is in framing a testable question: if semaglutide reduces reward-seeking in people with substance-use disorders, and if MOH is partly driven by an addiction-like reward circuit, then a prospective randomised trial in MOH patients would be the right test. No such trial is registered in public databases as of August 2026.

The established path for MOH treatment is detoxification: stopping the overused drug and managing withdrawal. Preventive therapies for the underlying migraine, including beta-blockers, topiramate, and CGRP-pathway monoclonal antibodies, are then introduced to reduce attack frequency and, by doing so, reduce the pressure to use acute medication. Adding a GLP-1 class drug as an adjunct to target the behavioural component is the hypothesis at stake. Whether the triptan reduction in the Roland et al data reflects that mechanism, or simply weight-driven migraine improvement, or some combination, has not been answered.

What this means for people with migraine now

Semaglutide is licensed for type-2 diabetes and chronic weight management, not for migraine or MOH. No regulatory body has approved any GLP-1 receptor agonist for a headache indication as of writing. For current regulatory status of semaglutide, see the semaglutide overview page and the US regulation hub. Using semaglutide off-label to manage MOH would carry the full adverse-event profile of the drug, including a substantial gastrointestinal burden, without any evidence base specific to that use.

Anyone experiencing frequent headache that may be linked to analgesic use should discuss the pattern with a headache specialist or neurologist, not attempt to manage it by adding a GLP-1 drug obtained off-label. The editorial's contribution is in directing researchers toward a testable hypothesis. Whether that hypothesis holds in a controlled trial is a question the literature has not yet answered.